CD19 and diffuse large B-cell lymphoma: At the meeting, a single-center, phase 1 dose-escalation clinical trial (NCT04088890) revealed that CD22 CAR-T cell therapy mediated high durable remission rates in 21 patients with DLBCL who relapsed after prior CD19 CAR-T treatment.